Get the Stockscreener App
4.56
8.06%
-0.40
Precision Biosciences Inc stock is traded at $4.56, with a volume of 278.57K.
It is down -8.06% in the last 24 hours and down -3.39% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.96
Open:
$4.91
24h Volume:
278.57K
Relative Volume:
0.62
Market Cap:
$34.98M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-6.9091
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
-15.24%
1M Performance:
-3.39%
6M Performance:
-53.85%
1Y Performance:
-60.10%
1-Day Range:
$4.55
$5.00
1-Week Range:
$4.55
$5.545
52-Week Range:
$3.61
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.56 | 34.98M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences (DTIL) Poised for Growth with ARCUS Technology and Strategic Partnerships - HPBL
Allogene Therapeutics vs. Precision BioSciences: A Deep Dive into Two Promising Gene Therapy Stocks – Market - HPBL
Geode Capital Management LLC Raises Holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) - Defense World
Precision BioSciences (NASDAQ:DTIL) Earns “Buy” Rating from HC Wainwright - Defense World
Precision BioSciences (NASDAQ:DTIL) Raised to “Outperform” at BMO Capital Markets - Defense World
BMO Capital Upgrades Precision BioSciences (DTIL) - MSN
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst - Benzinga
Precision BioSciences Shares Surge 60% After Breakthrough Clinical Results for OTC Deficiency Treatment - HPBL
Precision Bio stock upgraded at BMO (update) (DTIL:NASDAQ) - Seeking Alpha
Precision BioSciences upgraded to Outperform at BMO on favorable risk/reward - Investing.com Canada
Pre-Market Surge For Precision BioSciences (DTIL) On Groundbreaking Trial Data - Stocks Telegraph
Precision BioSciences shares soar on promising gene editing trial results By Investing.com - Investing.com Australia
Precision BioSciences shares soar on promising gene editing trial results - Investing.com
Head-To-Head Review: Allogene Therapeutics (NASDAQ:ALLO) versus Precision BioSciences (NASDAQ:DTIL) - Defense World
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - BioSpace
DTILPrecision BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease - The Scientist
Precision BioSciences Gene Therapy Shows Breakthrough Success in Infant OTC Deficiency Trial - StockTitan
Precision BioSciences projects extended cash runway into 2026 - Investing.com
Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer's Disease - PR Newswire
Precision Biosciences director Germano purchases $16,186 in stock By Investing.com - Investing.com Canada
Insider Buying: Geno Germano Acquires Shares in Precision BioSci - GuruFocus.com
Precision Biosciences director Germano purchases $16,186 in stock - Investing.com
Precision BioSciences stock hits 52-week low at $4.12 By Investing.com - Investing.com Canada
Precision Biosciences director Kevin Buehler buys $21,081 in stock By Investing.com - Investing.com Nigeria
Precision BioSciences stock hits 52-week low at $4.12 - Investing.com India
Precision Biosciences CFO buys $10,036 in common stock By Investing.com - Investing.com Canada
Insider Buying: Kevin Buehler Acquires Shares of Precision BioSc - GuruFocus.com
Insider Buying: John Kelly Acquires Shares of Precision BioScien - GuruFocus.com
Precision Biosciences director Kevin Buehler buys $21,081 in stock - Investing.com
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):